Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Published by欻奠 黄 Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration."— Presentation transcript:

1 Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. (A and B) Serial measurements of liver stiffness using transient elastography after the start of dezamizumab infusion on day 1 in subjects with hepatic amyloidosis. Predose measurements before each dezamizumab infusion are indicated by PD. Median normal liver stiffness, 5.3 kPa (90% of individuals are <7.0 kPa). (A) Graph shows subjects with initial baseline liver stiffness ≤15kPa. Subject 007 () received sequential doses of 152, 600, and 2000 mg of dezamizumab. Subject 008 () received sequential doses of 246 and 600 mg. Subject 013 () received sequential doses of 650 and 600 mg. Subject 014 () received sequential doses of 600, 1000, and 500 mg. Subject 015 () received sequential doses of 600 and 2000 mg. (B) Graph shows subjects with initial baseline liver stiffness >15kPa. Subject 009 () received sequential doses of 637, 1000, and 2000 mg. Subject 010 () received sequential doses of 400, 1200, and 2000 mg. Subject 011 () received sequential doses of 650, 1000, and 2000 mg. Subject 016 () received sequential doses of 600, 2000, and 2000 mg. Subject 019 () received a single dose of 2000 mg. The interval between doses was variable: range, 3 to 12 months. (C) Serial measurements of the concentration of circulating NT-proBNP after dezamizumab treatment in subjects with proven cardiac amyloidosis. All available results are shown. S, value at screening before study; PD, predose value before each dezamizumab infusion; NT-proBNP, N-terminal pro–B-type natriuretic peptide. Results after first dose are shown on an expanded scale. Subject 018 (AL type) () received sequential doses of 600, 1200, and 1200 mg of dezamizumab. Subject 020 (AL) () received a single dose of 600 mg. Subject 021 (AL) () received sequential doses of 600, 1200, and 1200 mg. Subject 023 [transthyretin amyloidosis (ATTR)] () received a single dose of 1200 mg. Subject 024 (ATTR) () received a single dose of 1000 mg. Subject 025 (ATTR) () received a single dose of 600 mg. The interval between doses was variable: range, 2 to 3 months. Duncan B. Richards et al., Sci Transl Med 2018;10:eaan3128 Published by AAAS

Download ppt "Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration."

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
Stephen W. Waldo et al. JACC 2008;51:

Stephen W. Waldo et al. JACC 2008;51:
Median NT-proBNP levels (pg/mL) by GFR and 60-day survival

Median NT-proBNP levels (pg/mL) by GFR and 60-day survival
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.
Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
Effects of highly concentrated SFN provided as BSE in T2D patients

Effects of highly concentrated SFN provided as BSE in T2D patients
Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.
Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.
Increased ADMA in pregnancy is associated with SGA birth outcomes

Increased ADMA in pregnancy is associated with SGA birth outcomes

Similar presentations

Ads by Google